230 related articles for article (PubMed ID: 19698110)
21. SETD2 mutation in renal clear cell carcinoma suppress autophagy via regulation of ATG12.
González-Rodríguez P; Engskog-Vlachos P; Zhang H; Murgoci AN; Zerdes I; Joseph B
Cell Death Dis; 2020 Jan; 11(1):69. PubMed ID: 31988284
[TBL] [Abstract][Full Text] [Related]
22. Expression and prognostic value of NSD1 and SETD2 in pancreatic ductal adenocarcinoma and its precursor lesions.
Ettel M; Zhao L; Schechter S; Shi J
Pathology; 2019 Jun; 51(4):392-398. PubMed ID: 31060750
[TBL] [Abstract][Full Text] [Related]
23. Functional Studies on Primary Tubular Epithelial Cells Indicate a Tumor Suppressor Role of SETD2 in Clear Cell Renal Cell Carcinoma.
Li J; Kluiver J; Osinga J; Westers H; van Werkhoven MB; Seelen MA; Sijmons RH; van den Berg A; Kok K
Neoplasia; 2016 Jun; 18(6):339-46. PubMed ID: 27292023
[TBL] [Abstract][Full Text] [Related]
24. Reduced mRNA expression levels of NFE2L2 are associated with poor outcome in breast cancer patients.
Wolf B; Goebel G; Hackl H; Fiegl H
BMC Cancer; 2016 Oct; 16(1):821. PubMed ID: 27770790
[TBL] [Abstract][Full Text] [Related]
25. The methyltransferase SETD2 couples transcription and splicing by engaging mRNA processing factors through its SHI domain.
Bhattacharya S; Levy MJ; Zhang N; Li H; Florens L; Washburn MP; Workman JL
Nat Commun; 2021 Mar; 12(1):1443. PubMed ID: 33664260
[TBL] [Abstract][Full Text] [Related]
26. Evidence of a tumour suppressive function of E2F1 gene in human breast cancer.
Worku D; Jouhra F; Jiang GW; Patani N; Newbold RF; Mokbel K
Anticancer Res; 2008; 28(4B):2135-9. PubMed ID: 18751386
[TBL] [Abstract][Full Text] [Related]
27. SETD2 alterations and histone H3K36 trimethylation in phyllodes tumor of breast.
Tsang JY; Lai ST; Ni YB; Shao Y; Poon IK; Kwan JS; Chow C; Shea KH; Tse GM
Breast Cancer Res Treat; 2021 Jun; 187(2):339-347. PubMed ID: 33844099
[TBL] [Abstract][Full Text] [Related]
28. The mRNA expression of DAP3 in human breast cancer: correlation with clinicopathological parameters.
Wazir U; Jiang WG; Sharma AK; Mokbel K
Anticancer Res; 2012 Feb; 32(2):671-4. PubMed ID: 22287761
[TBL] [Abstract][Full Text] [Related]
29. Histone methyltransferase SETD2 inhibits tumor growth via suppressing CXCL1-mediated activation of cell cycle in lung adenocarcinoma.
Zhou Y; Zheng X; Xu B; Deng H; Chen L; Jiang J
Aging (Albany NY); 2020 Nov; 12(24):25189-25206. PubMed ID: 33223508
[TBL] [Abstract][Full Text] [Related]
30. Downregulation of the histone methyltransferase SETD2 promotes imatinib resistance in chronic myeloid leukaemia cells.
Sheng Y; Ji Z; Zhao H; Wang J; Cheng C; Xu W; Wang X; He Y; Liu K; Li L; Voeltzel T; Maguer-Satta V; Gao WQ; Zhu HH
Cell Prolif; 2019 Jul; 52(4):e12611. PubMed ID: 31054182
[TBL] [Abstract][Full Text] [Related]
31. The Iws1:Spt6:CTD complex controls cotranscriptional mRNA biosynthesis and HYPB/Setd2-mediated histone H3K36 methylation.
Yoh SM; Lucas JS; Jones KA
Genes Dev; 2008 Dec; 22(24):3422-34. PubMed ID: 19141475
[TBL] [Abstract][Full Text] [Related]
32. Roles of SETD2 in Leukemia-Transcription, DNA-Damage, and Beyond.
Skucha A; Ebner J; Grebien F
Int J Mol Sci; 2019 Feb; 20(5):. PubMed ID: 30818762
[TBL] [Abstract][Full Text] [Related]
33. miR-142-3p as tumor suppressor miRNA in the regulation of tumorigenicity, invasion and migration of human breast cancer by targeting Bach-1 expression.
Mansoori B; Mohammadi A; Ghasabi M; Shirjang S; Dehghan R; Montazeri V; Holmskov U; Kazemi T; Duijf P; Gjerstorff M; Baradaran B
J Cell Physiol; 2019 Jun; 234(6):9816-9825. PubMed ID: 30480817
[TBL] [Abstract][Full Text] [Related]
34. A New Chromatin-Cytoskeleton Link in Cancer.
Giaccia AJ
Mol Cancer Res; 2016 Dec; 14(12):1173-1175. PubMed ID: 27528705
[TBL] [Abstract][Full Text] [Related]
35. [mRNA expression of CK19 and CEA in peripheral blood of patients with breast cancer detected by real-time quantitative PCR].
Zheng HY; Chen Q; Ye YB; Huang WW
Zhonghua Yi Xue Za Zhi; 2008 Aug; 88(32):2267-70. PubMed ID: 19087676
[TBL] [Abstract][Full Text] [Related]
36. P14ARF is down-regulated during tumour progression and predicts the clinical outcome in human breast cancer.
Wazir U; Jiang WG; Yasaei H; Linne H; Newbold RF; Mokbel K
Anticancer Res; 2013 May; 33(5):2185-9. PubMed ID: 23645774
[TBL] [Abstract][Full Text] [Related]
37. Functional role of
Linne H; Yasaei H; Marriott A; Harvey A; Mokbel K; Newbold R; Roberts T
Oncotarget; 2017 Sep; 8(37):61890-61900. PubMed ID: 28977912
[TBL] [Abstract][Full Text] [Related]
38. SPOP-containing complex regulates SETD2 stability and H3K36me3-coupled alternative splicing.
Zhu K; Lei PJ; Ju LG; Wang X; Huang K; Yang B; Shao C; Zhu Y; Wei G; Fu XD; Li L; Wu M
Nucleic Acids Res; 2017 Jan; 45(1):92-105. PubMed ID: 27614073
[TBL] [Abstract][Full Text] [Related]
39. Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia.
Parker H; Rose-Zerilli MJ; Larrayoz M; Clifford R; Edelmann J; Blakemore S; Gibson J; Wang J; Ljungström V; Wojdacz TK; Chaplin T; Roghanian A; Davis Z; Parker A; Tausch E; Ntoufa S; Ramos S; Robbe P; Alsolami R; Steele AJ; Packham G; Rodríguez-Vicente AE; Brown L; McNicholl F; Forconi F; Pettitt A; Hillmen P; Dyer M; Cragg MS; Chelala C; Oakes CC; Rosenquist R; Stamatopoulos K; Stilgenbauer S; Knight S; Schuh A; Oscier DG; Strefford JC
Leukemia; 2016 Nov; 30(11):2179-2186. PubMed ID: 27282254
[TBL] [Abstract][Full Text] [Related]
40. hTERT expression in human breast cancer and non-cancerous breast tissue: correlation with tumour stage and c-Myc expression.
Kirkpatrick KL; Ogunkolade W; Elkak AE; Bustin S; Jenkins P; Ghilchick M; Newbold RF; Mokbel K
Breast Cancer Res Treat; 2003 Feb; 77(3):277-84. PubMed ID: 12602927
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
